Kopei joined Amgen in May 2016 and provide leadership for key medical strategies, programs, and activities, and drive the interface with regional and global stakeholders, when Amgen building scientific presence and capabilities in Taiwan. In 2022, Kopei has been over 13 years experience in medical affairs with various roles of strategic advisors, clinical trials, field scientific engagement, medical governance across broad therapeutic areas and 11 years clinical practice at emergency medicine before joining the pharmaceutical industry.

Before joining Amgen, Kopei worked at GlaxoSmithKline during Jan 2009 – Apr 2016, where, as Country Medical Director in Taiwan, he spearheaded medical affairs, clinical operation and regulatory affairs teams. He led GSK Taiwan through the transformation of new external engagement model in the medical team. In a prior role, as Medical Advisor, he set up a team of medical scientific liaison for field scientific engagement at GSK Taiwan and provided expertise in support of respiratory, immunology, dermatology, neuroscience, oncology, metabolic, infection areas.

With a Doctor of Medicine, from National Yang Ming Medical University since 1996, Kopei underwent emergency medicine training, at Linkou Chang Gung Memorial Hospital and clinical practice in emergency and general medicine at Chang Gung Memorial Hospital, Keelung Hospital of MoHW, Mennonite Christian Hospital.

Dr. Chan is a physician epidemiologist with more than 30 years of global research experience in academia and private sector. He received medical training at National Taiwan University and advanced training in epidemiology at Harvard School of Public Health. He has served on the faculty at National Taiwan University (NTU) and Harvard School of Public Health and joined the private industry in 2005, subsequently became Chief Scientist of the Epidemiology Unit at Optum. Dr. Chan became a professor at NTU College of Medicine in 2013 and had been Director of the NTU Hospital Clinical Trial Center, Department of Medical Research, and NTU Health Data Research Center. He is transitioning to TriNetX (Vice President for Real World Evidence Consulting). Dr. Chan has authored or co-authored more than 150 peer-reviewed research articles and co-edited a textbook on pharmacoepidemiology. His H-index is 59 according to Google Scholar as of October 2022.

She obtained her PhD degree for Biochemical sciences at National Taiwan University and had 2 years post-Doc training at Academia Sinica. She has more than ten years medical affairs experience in pharmaceutical companies covering broad disease areas (cardiology, virology, hematology, and Oncology). She started as a MSL in Bayer and moved to BMS as a Medical advisor. She was then promoted to Disease Area Lead and had talent rotation for Japan-Korea-Taiwan cluster and global. She worked in above country role for more than 3 years and was Worldwide Medical contact point for Asia strategy.